WallStSmart

Edwards Lifesciences Corp (EW)vsRxsight Inc (RXST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Edwards Lifesciences Corp generates 4412% more annual revenue ($6.07B vs $134.48M). EW leads profitability with a 17.7% profit margin vs -29.0%. EW earns a higher WallStSmart Score of 55/100 (C).

EW

Buy

55

out of 100

Grade: C

Growth: 4.0Profit: 7.0Value: 7.3Quality: 4.8
Piotroski: 2/9

RXST

Avoid

34

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 5.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EWSignificantly Overvalued (-544.4%)

Margin of Safety

-544.4%

Fair Value

$12.31

Current Price

$82.67

$70.36 premium

UndervaluedFair: $12.31Overvalued

Intrinsic value data unavailable for RXST.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EW1 strengths · Avg: 8.0/10
Operating MarginProfitability
23.7%8/10

Strong operational efficiency at 23.7%

RXST1 strengths · Avg: 10.0/10
Price/BookValuation
0.9x10/10

Reasonable price relative to book value

Areas to Watch

EW4 concerns · Avg: 2.8/10
PEG RatioValuation
2.144/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

P/E RatioValuation
45.7x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-76.6%2/10

Earnings declined 76.6%

RXST4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$263.69M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-14.0%2/10

ROE of -14.0% — below average capital efficiency

Revenue GrowthGrowth
-18.9%2/10

Revenue declined 18.9%

Comparative Analysis Report

WallStSmart Research

Bull Case : EW

The strongest argument for EW centers on Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 23.7%. Revenue growth of 13.3% demonstrates continued momentum.

Bull Case : RXST

The strongest argument for RXST centers on Price/Book.

Bear Case : EW

The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 45.7x leaves little room for execution misses.

Bear Case : RXST

The primary concerns for RXST are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

EW profiles as a mature stock while RXST is a turnaround play — different risk/reward profiles.

RXST carries more volatility with a beta of 1.15 — expect wider price swings.

EW is growing revenue faster at 13.3% — sustainability is the question.

EW generates stronger free cash flow (354M), providing more financial flexibility.

Bottom Line

EW scores higher overall (55/100 vs 34/100), backed by strong 17.7% margins and 13.3% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Edwards Lifesciences Corp

HEALTHCARE · MEDICAL DEVICES · USA

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.

Visit Website →

Rxsight Inc

HEALTHCARE · MEDICAL DEVICES · USA

Rxsight Inc. is a pioneering healthcare technology company specializing in advanced vision correction solutions through its innovative diagnostic and surgical techniques in refractive eye surgery. Utilizing proprietary software and precision-guided laser technology, the company significantly improves patient outcomes and overall quality of life. Rxsight's strong intellectual property portfolio and strategic partnerships further enhance its competitive positioning within the expanding ophthalmic market. With a robust commitment to innovation and excellence, Rxsight is strategically poised for significant growth and impact in the evolving landscape of eye care.

Want to dig deeper into these stocks?